Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Meningioma × brigatinib × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 20 Lung Neoplasms 9 Lymphoma, Large-Cell, Anaplastic 4 Carcinoma 4 Carcinoma, Squamous Cell 2 Carcinoma, Large Cell 2 Brain Neoplasms 2 Adenocarcinoma 2 ALK-positive Advanced NSCLC 2 Sexual Dysfunction, Physiological 1 Neuroma, Acoustic 1 Neurofibromatosis 2 1 Neoplasms 1 Neoplasm Metastasis 1 NSCLC 1 Meningioma 1 Granuloma, Plasma Cell 1 Gastrointestinal Neoplasms 1 Eunuchism 1 Erectile Dysfunction 1 Ependymoma 1 Disease Progression 1 Carcinoma, Pancreatic Ductal 1 Breast Neoplasms 1 ALK-positive NSCLC 1 ALK+ Advanced NSCLC 1

Interventions

Magnetic Resonance Spectroscopy 14 Hydroxyurea 7 Everolimus 7 lutetium Lu 177 dotatate 6 gallium Ga 68 dotatate 6 Radiosurgery 6 Proton Therapy 6 Specimen Handling 5 Bevacizumab 5 pembrolizumab 4 Surveys and Questionnaires 4 Radiotherapy 4 Imatinib Mesylate 4 Cyclophosphamide 4 abemaciclib 3 Tranexamic Acid 3 Temozolomide 3 Surgical Procedures, Operative 3 Sunitinib 3 Radiotherapy, Intensity-Modulated 3 Observation 3 Nivolumab 3 Ga(III)-DOTATOC 3 90Y-octreotide, DOTA-Tyr(3)- 3 trametinib 2 fludarabine 2 arginyllysine 2 aldesleukin 2 Yoga 2 Whole Body Imaging 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04374305 2026-01-12

INTUITT-NF2

Massachusetts General Hospital

Phase 2 Active not recruiting

Ependymoma, Meningioma, Neuroma, Acoustic, Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon ⚡